Alexion Pharmaceuticals announced this week that it is buying Syntimmune in a deal that could be worth $1.2 billion.
The purchase will include Syntimmune’s portfolio of treatments for rare diseases including SYNT001, a medication that autoimmune hemolytic anemia. The deal is another step in Alexion’s bid to bolster its pipeline for drugs that treat rare disorders and diversify the company’s clinical-stage portfolio.
Alexion also announced that it is buying Wilson Therapeutics for $855 million in April. As part of the deal with Syntimmune, Alexion will make an initial payment of $400 million and then add additional payments worth up to $800 million, pending certain drug development milestones.
Read the full Reuters report.
[javascriptSnippet]